Isotopen in Nucleaire Geneeskunde

GE HealthCare heeft een rijke historie aan radiotracers en isotopen met toepassingen binnen de nucleaire geneeskunde, zowel in het SPECT als in het PET segment

15+

innovative solutions launched in 15 years

patients served every year

3 cGMP

certified molecular imaging production facilities globally

10,000+

doses delivered worldwide for clinical trials since 2018

Products

MOLECULAR IMAGING IN PRECISION MEDICINE

Our focus is on precision medicine – an innovative approach to tailoring disease prevention and diagnosis with the best possible treatment pathway. We bring clinically relevant applications to our healthcare professionals and work to improve access to nuclear medicine – transforming patient outcomes.

PHARMA SERVICES

Accelerating therapeutic research to improve patient lives

Our Pharma Services offering provides access to GE Healthcare's tracer portfolio, which can be tailored to the needs of your clinical study. Our biomarkers enable you to select the right patients, and monitor patient progression long-term, so you can test your hypothesis more accurately.

We also have an established global network of suppliers, and a dedicated in-house team, supporting you in keeping your project on track. Our many years of experience in managed dose supply mean that you can plan and schedule patients with confidence.

IMMUNO-ONCOLOGY

Molecular imaging can support the research and development of treatments that can take advantage of the body’s own immune system to help fight cancer.

Our growing understanding of patients' immune responses is aiding the development of PET diagnostic tools for clinical management of immunotherapy patients, to help in identifying patients who are more likely to respond, avoiding unnecessary treatment and reducing adverse events. We develop these tools by collaborating with third parties and leading academic institutions like Vanderbilt University Medical Center in the USA.

NEW TRACERS

We are committed to bringing innovative solutions to patients.

We welcome the opportunity to collaborate with leading academic institutions, biotech and pharmaceutical companies to innovate in molecular imaging across disease areas to enable clinicians to better diagnose, treat and monitor complex diseases and to advance care for patients with unmet needs. For information on business development or partnering opportunities, please contact us below registering your interest about our Pharmaceutical Diagnostics Licensing department.

APPLYING DIGITAL TOOLS

We use software to analyse complex medical data and relationships between prevention, or treatment techniques, and patient outcomes.

Our quantification software enables visual evaluation and quantification of SPECT and PET images, allowing clinicians to remotely access and review clinical images from virtually any computer system anytime, anywhere in the world.

Also our Edison™ Platform offers integrated artificial intelligence powered technologies, helping you make sound diagnostic decisions, operate at peak efficiency and deliver positive patient outcomes.

Innovation

The future of molecular imaging is personal

Melden van Bijwerkingen

GE Healthcare heeft een verplichting om de volksgezondheid te beschermen door de veiligheid en effectiviteit van onze producten te waarborgen. Om dit te doen, verzamelen we rapporten van vermoedelijke bijwerkingen die patiënten ervaren tijdens of na blootstelling aan onze producten. Ook verzamelen we informatie over bijzondere situaties (zoals gebruik tijdens zwangerschap, overdosering etc.), evenals klachten en andere opmerkingen. Neem contact op met Benelux.PVcomplaint@ge.com om een vermoedelijk ongewenst voorval / incident, speciale situatie, klacht te melden of om opmerkingen achter te laten. Tel: +31 40 299 1000

JB00248NL 02-2023

JB00248NL